Premium
Combined oral contraceptives and liver cancer
Author(s) -
Molina Ramiro,
Martinez Luis,
Salas Oriana,
Dabancens Aifredo,
Yun Tao,
ZhiHeng Chen,
YongWei Hu,
Cuadros Alvaro,
Aristizabal Nubia,
Modan Baruch,
Ron Elaine,
Alfandary Esther,
Mati J. G.,
Kenya Patrick,
Kungu Alfred,
Gatei D.,
Ibeziako Patrick A.,
Abioye A. A.,
Junaid T. A.,
Aghadiuno Patrick U.,
Apelo Ruben A.,
De LaCruz Julietta R.,
Baens Jose,
Canlas Benjamin D.,
Silpisornkosol Suporn,
Pardthaisong Tieng,
Sivasomboom Boonlong,
Theetrat Choti,
Boosiri Banpot,
Chutivongse Supawat,
Virutamasen Pramuan,
Wongsrichanalai Chansuda,
Sindhvananda Sermsri,
Koetsawang Suporn,
Rachawat Duangdao,
Kiriwat Orawan,
Chantarakul Nivat,
Anthony P. P.,
Thomas David B.,
Stanford Janet L.,
Ray Roberta M.,
Noonan Elizabeth A.,
Holck Susan
Publication year - 1989
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910430215
Subject(s) - medicine , liver cancer , cancer , family planning , hepatocellular carcinoma , relative risk , gynecology , liver disease , population , hepatitis , obstetrics , environmental health , research methodology , confidence interval
A multi‐national, hospital‐based, case‐control study was conducted to evaluate the possible relationships of steroid contraceptives to 6 neoplasms. Based on data from 122 newly diagnosed cases of primary liver cancer and 802 matched controls, the relative risk of liver cancer in women who had ever used combined oral contraceptives was estimated to be 0.71 (95% Cl 0.4–1.2). No consistent trend in risk with months of use or time since first or last use was observed. Separate analyses also revealed no association between use of combined oral contraceptives and hepatocellular carcinoma (RR = 0.60) or cholangiocarcinoma (RR = 1.22). Most women in this study came from areas in which hepatitis B is endemic and rates of liver cancer are relatively high, and in most cases use of oral contraceptives was of short duration. These results provide no evidence that short‐term use of oral contraceptives enhances risk of liver cancer in countries where the determinants of this disease are similar to those observed in the countries where this study was conducted.